Pristiq Extended-Release (desvenlafaxine succinate) — NDC 0008-1222 by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Pristiq Extended-Release (desvenlafaxine succinate) — NDC 0008-1222 by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. is one of 9,000 drug products in the NDCLookup dataset. Key details — Brand name: Pristiq Extended-Release; Generic name: desvenlafaxine succinate; Product NDC: 0008-1222.
| Brand name | Pristiq Extended-Release |
|---|---|
| Generic name | desvenlafaxine succinate |
| Product NDC | 0008-1222 |
| Labeler | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active ingredients | DESVENLAFAXINE SUCCINATE 100 mg/1 |
| Pharmacologic class | Cytochrome P450 2D6 Inhibitors [MoA], Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC] |
| Marketing category | NDA |
| Product type | HUMAN PRESCRIPTION DRUG |
| Source | openFDA NDC Directory |
$899/mo
Try NDCLookup →